Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

Eli Lilly reported that two additional Phase 3 trials of its obesity drug retatrutide delivered positive results and it plans to submit an FDA application in Q1 of next year. This advances the path toward potential regulatory approval and commercial launch, supporting a favorable outlook for the program.

Analysis

Eli Lilly reported that two additional Phase 3 trials of its obesity drug retatrutide delivered positive results and it plans to submit an FDA application in Q1 of next year. This advances the path toward potential regulatory approval and commercial launch, supporting a favorable outlook for the program.